Your browser doesn't support javascript.
loading
A 2-year review of publicly funded cell-free DNA screening in Ontario: utilization and adherence to funding criteria.
Bellai-Dussault, Kara; Meng, Lynn; Huang, Tianhua; Reszel, Jessica; Walker, Mark; Lanes, Andrea; Okun, Nan; Armour, Christine; Dougan, Shelley.
Afiliação
  • Bellai-Dussault K; Better Outcomes Registry & Network (BORN) Ontario, Ottawa, Ontario, Canada.
  • Meng L; Children's Hospital of Eastern Ontario (CHEO) Research Institute, Ottawa, Ontario, Canada.
  • Huang T; Better Outcomes Registry & Network (BORN) Ontario, Ottawa, Ontario, Canada.
  • Reszel J; Better Outcomes Registry & Network (BORN) Ontario, Ottawa, Ontario, Canada.
  • Walker M; North York General Hospital, Toronto, Ontario, Canada.
  • Lanes A; The Institute of Health Policy, Management and Evaluation & Department of Obstetrics & Gynaecology, University of Toronto, Toronto, Ontario, Canada.
  • Okun N; Better Outcomes Registry & Network (BORN) Ontario, Ottawa, Ontario, Canada.
  • Armour C; Children's Hospital of Eastern Ontario (CHEO) Research Institute, Ottawa, Ontario, Canada.
  • Dougan S; Better Outcomes Registry & Network (BORN) Ontario, Ottawa, Ontario, Canada.
Prenat Diagn ; 40(2): 164-172, 2020 01.
Article em En | MEDLINE | ID: mdl-31525278
OBJECTIVE: Ontario offers a publicly funded modified contingent model of prenatal screening for aneuploidy in which cell-free DNA (cfDNA) screening is covered for pregnancies at higher risk of fetal aneuploidy. The objective of this study was to review utilization of provincially funded cfDNA screening and adherence to the criteria laid out in Ontario prenatal screening guidelines. METHODS: This was a descriptive cohort study using data collected by Ontario's prescribed maternal and child registry. The study population included all pregnant individuals who received cfDNA screening from January 2016 to December 2017. RESULTS: The most common criteria for provincially funded cfDNA screening were advanced maternal age ≥40 years (37.7%), positive multiple marker screen (34.1%), modifying risk factors such as ultrasound soft markers (7.1%), and previous aneuploidy (5.5%). The audit demonstrated that 2.9% of funded cfDNA screens tests did not meet funding criteria, and that 11.4% of self-paid cfDNA screens could have been publicly funded. CONCLUSION: Reviewing and auditing the application of criteria for funded cfDNA screening using prescribed registry data allows an opportunity to identify areas where targeted education may improve adherence to standardized screening protocols, and provides a basis for reassessment of the funding model.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Governo Estadual / Fidelidade a Diretrizes / Definição da Elegibilidade / Financiamento Governamental / Teste Pré-Natal não Invasivo / Aneuploidia Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Female / Humans / Pregnancy País/Região como assunto: America do norte Idioma: En Revista: Prenat Diagn Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Governo Estadual / Fidelidade a Diretrizes / Definição da Elegibilidade / Financiamento Governamental / Teste Pré-Natal não Invasivo / Aneuploidia Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Female / Humans / Pregnancy País/Região como assunto: America do norte Idioma: En Revista: Prenat Diagn Ano de publicação: 2020 Tipo de documento: Article